In immunocompromised patients, Toxoplasma gondii infections may constitute a cause of life-threatening disease. The persistence of viable parasites in tissues after a primary infection is considered the major cause of morbidity of toxoplasmosis in these patients, but transmission via leukocyte transfusions and organ transplants has also been reported (10, 11, 28) . In heart transplant recipients, disseminated toxoplasmosis has been described to occur at a relatively high frequency compared with the occurrence of the disease in recipients of liver or kidney transplants (6, 12, 20) . Active infections found in transplanted hearts indicate the donor heart as the most likely source of infection (12, 19, 29) .
Cyclosporine in combination with low-dose steroids is presently routinely used as immunosuppressive therapy in transplantation. Depression of toxoplasma-specific antibody responses after cyclosporine administration and an antiparasitic activity of the drug have been described (20, 22) . Therefore, it is important to determine the value of serology for the diagnosis of active toxoplasma infection in cyclosporine-treated heart-transplant recipients. We report our experience with indirect enzyme-linked immunosorbent assays (ELISAs) for specific immunoglobulin G (IgG) and IgM (ELISA-IgG and ELISA-IgM), two IgM antibody capture assays, and an IgM immunoblotting test in a series of 43 heart transplant recipients. * Corresponding author.
MATERIALS AND METHODS
Patients. Between June 1984 and July 1987, 42 patients underwent orthotopic heart transplantation at the University Hospital Dijkzigt in Rotterdam. One patient needed a retransplantation after 9 months because of chronic rejection. Two patients did not survive 1 week after surgery and were excluded from this study. Another three patients that received transplants at other institutions were included. The follow-up period ranged from 9 to 45 months.
Immunosuppressive therapy. Basic immunosuppressive therapy consisted of cyclosporine and low-dose prednisone. Preoperatively, cyclosporine was administered with a starting dose of 3 mg/kg per day. One week postoperatively, this dose was adjusted according to renal function and targeted to blood levels of 150 to 200 ng/ml for the remainder of the first year and to 100 to 150 ng/ml after that. Perioperatively, patients received prednisolone intravenously followed by oral prednisone as soon as possible in doses of 1 mg/kg per day tapered in 6 weeks to 10 Antitoxoplasma antibodies were not detected in sera of 15 (35%) patients. Three patients underwent heart transplantation at other institutions; no preoperative serology from two of the three recipients or from any of the three donors was available. At admission to our center, sera of the two recipients with unknown preoperative serology contained antitoxoplasma antibodies.
The use of rabbit antithymocyte globulin was found not to affect serology in this study.
Seronegative recipients. (i) Serologic results. IgG was found immediately after transplantation in sera of 9 of the 15 seronegative recipients with indirect ELISA titers of up to 1:160. This IgG could not be detected any more after 4 to 6 weeks and was apparently passively acquired by blood transfusion, since none of these patients received cytomegalovirus hyperimmune serum.
Eight (53%) of the fifteen seronegative recipients ( However, the patient recovered while on sulfadiazine-pyrimethamine therapy.
Numerous toxoplasma tissue cysts appeared at the time of seroconversion in sections of endomyocardial biopsies from patient 5. Tachyzoites were not detected. The finding of a single tissue cyst in an endomyocardial biopsy, routinely taken 67 weeks after transplantation from recipient 18, led to administration of sulfadiazine-pyrimethamine.
In patient 23, a computed tomographic brain scan showed hypodense mass lesions in the capsula interna and the subinsular region suggestive of hemorrhagic infarcts and was treated accordingly. After progressive neurologic dysfunction was found, the prophylactic spiramycin was replaced by sulfadiazine-pyrimethamine therapy. Five days later the patient improved, but fever developed again the next day. The patient died after bradycardia and cardiac arrest 10 days after the start of specific therapy.
(iii) Histopathologic results. 24 , IgG complexes were detected in serum of the heart donor.
No transfusions other than those at surgery were given.
Administration of hyperimmune globulin against cytomegalovirus and changes in antibody titer did not correlate. The medical records of the patients did not show clinical symptoms or signs that could directly be attributed to active infections with T. gondii.
DISCUSSION
The common route of T. gondii infection in heart transplantation is associated with reception of the heart of a seropositive donor. Approximately 50% of the recipients in the present study received hearts from such donors. This figure corresponds rather well with the average seropositivity of the population in The Netherlands. The about 50% seropositive heart donors and nearly 40% seronegative recipients in our patient series indicate that active toxoplasma infections can be expected to occur relatively frequently in cardiac transplant recipients in The Netherlands.
Another source of infection might be blood transfusions. Seroconversions in seronegative recipients and onset of increase in antibody levels in seropositive recipients were found to occur during the first 2 months after surgery and in one case after an episode of increased immunosuppression 3.5 months posttransplantation. These observations are in agreement with findings in other heart transplant patients (20, 37) . In recipients described by Luft et al. (20) , peak titers in dye test were reached as early as 3 to 13 weeks posttransplantation. However, most of their patients received azathioprine in combination with rabbit antithymocyte globulin and corticosteroids. The use of cyclosporine in immunosuppressive treatment in the present study might explain the more gradual rise in antibody levels found (20, 22) . The rise in antibody titer 3.5 months after surgery in a seropositive recipient indicates that the possibility of active toxoplasma infection should still be considered outside the direct posttransplant period of the first 2 months during and after episodes of increased immunosuppression. However, clinically apparent disease in reactivated infections appears to be rare (20) .
In seropositive recipients, changes in IgM antibody levels were detected only with indirect ELISA. It is not clear why acELISA did not measure these changes, except that indirect ELISA determines the concentration of antitoxoplasma antibodies and acELISA determines the percentage of total IgM reactive with toxoplasma antigen. In establishing endpoint titers in indirect ELISA, a larger range of antibody affinities to toxoplasma antigens may be used than in acELISA, in which measurements of absorbances at low sample dilutions may be more correlated with high affinity antibodies (17) (30, 35) . Because of insufficient quantities of specific serum specimens, data on the occurrence of circulating antigens in seronegative recipients are incomplete and do not allow conclusions.
IgM immunoblotting of sera from seropositive recipients revealed in one case (patient 40) weakly reactive antibodies to 6-kDa antigens. These antibodies are supposed not to be present in sera from chronic infections and are absent in negative controls (9, 24) . Nevertheless, in IgM blots, falsepositive results appear not to occur with regard to 6-kDa antigens (26) . Discrepancies between results of both IgM ELISAs and IgM blot (e.g., heart donor serum of patient 38) might also be due in part to differences between affinities of measured antibodies in the assays. The relatively long period during which 6-kDa IgM-reactive antibodies were found (patient 37) indicates that detection of recent infections with blotting can be hampered by the long-lasting presence of such antibodies in individuals.
Despite extensive search and use of sensitive techniques to detect parasites or parasitic antigens (4, 21, 34) , organisms
were not demonstrated at autopsy in patient 23. Histopathological inspection of brain tissue revealed phenomena that were considered more compatible with virus infection than with T. gondii infection (1, 3) . It is therefore not unlikely that this patient did not have toxoplasmosis at death. Since fatal infection may develop in the seronegative recipient of a heart of a seropositive donor, it was decided to use prophylaxis in patients belonging to this high-risk group. Prophylaxis is based upon killing or inhibition of proliferation of parasites. However, the effective levels of antiparasitic drugs in serum and body fluids have not been determined. Synergistic action of sulfadiazine and pyrimethamine on parasites outside mature tissue cysts has long been known from experimental infections. Less is known about efficacy of pyrimethamine alone, but it is claimed to prevent toxoplasmosis in heart transplant recipients (12, 38) . Also, in vitro studies suggest that sustained high levels of pyrimethamine in blood may be effective against toxoplasmosis (13) , but caution must be exerted when extrapolating these data to in vivo efficacy. However, bone marrow toxicity is a disadvantage of using pyrimethamine. Spiramycin was used in the present study as prophylaxis for the development of myocarditis and further dissemination of infection. This VOL. 27, 1989 on November 6, 2017 by guest http://jcm.asm.org/ 534 SLUITERS ET AL. macrolide has been shown to prevent transplacental infection in humans (5) , and hepatotoxicity and interference with concomitant administrated drugs have never been described (7, 16, 23) . However, despite spiramycin prophylaxis, 3 g/day, seroconversion occurred, and the data suggest that spiramycin should not be used for this purpose. Another serious drawback in the use of spiramycin is that it cannot prevent neurotoxoplasmosis (16, 18) . Therefore, pyrimethamine instead of spiramycin should be studied further as the prophylactic drug. It appears justified to treat patients with combination therapy on seroconversion (20) 
